Annals of oncology : official journal of the European Society for Medical Oncology
Durvalumab with carboplatin/paclitaxel and bevacizumab followed by durvalumab and bevacizumab with or without olaparib maintenance in newly diagnosed non-BRCA-mutated advanced ovarian cancer.
P Harter, F Trillsch, A Okamoto, A Reuss, J-W Kim, M J Rubio-Pérez, M A Vardar, G Scambia, O Trédan, G-B Nyvang, N Colombo, M Bidziński, C Grimm, S Lheureux, E Van Nieuwenhuysen
Published: 202510.1016/j.annonc.2025.11.020
Abstract
BACKGROUND: Despite treatment advances in newly diagnosed advanced-stage ovarian cancer (aOC), improved outcomes are needed. PATIENTS AND METHODS: DUO-O (NCT03737643), a phase III placebo-controlled trial, enrolled patients with newly diagnosed aOC.…
Preview only. Read the full abstract at the source